Rhythm Biosciences Ltd (ASX: RHY) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Rhythm Biosciences Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $34.28 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 221.14 million
Earnings per share -0.038
Dividend per share N/A
Year To Date Return -82.83%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Rhythm Biosciences Ltd (ASX: RHY)
    Latest News

    In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
    Healthcare Shares

    2 ASX healthcare shares racing higher on positive updates

    These healthcare shares are avoiding the market weakness on Wednesday.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Healthcare Shares

    ASX All ords biotech stock explodes 120% on regulatory green light

    The company has hit a milestone with its cancer diagnostics test.

    Read more »

    A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
    Share Market News

    Guess which ASX All Ords share just crashed 52% on a TGA update

    Today was a day that shareholders of this medical diagnostics technology company won't forget in a hurry.

    Read more »

    A businessman in a suit wears a medal around his neck and raises a fist in victory surrounded by two other businessmen in suits facing the other direction to him.
    Share Gainers

    It's not all bad news for ASX All Ords shares today. Here are some big winners

    Why are these ASX All Ords shares lifting?

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Healthcare Shares

    2 ASX healthcare shares smashing the All Ords today

    These healthcare shares are smashing the All Ords today...

    Read more »

    busy trader on the phone in front of board depicting asx share price risers and fallers
    Healthcare Shares

    The chair of this ASX All Ords company just sold $6.5 million of shares. What gives?

    Here's why this ASX All Ords company chair sold off a portion of his holdings...

    Read more »

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    Rhythm Biosciences share price lifts 5% on TGA news

    The company is hoping to market and sell its cancer test kit in Australia this year.

    Read more »

    Lab worker puts hands in the air and dances around
    Healthcare Shares

    Here's why the Rhythm Biosciences (ASX:RHY) share price soared 8% today

    Shares in the healthcare company surged after the company released a quarterly update.

    Read more »

    Group of medical professionals high five
    Healthcare Shares

    Here's why the Rhythm (ASX:RHY) share price is up 11% today

    The company provided two exciting updates to investors this morning.

    Read more »

    man jumping along increasing bar graph signifying jump in alumina share price
    Healthcare Shares

    Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets

    The company is looking to launch into new markets.

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    Rhythm Biosciences (ASX: RHY) share price slumps amid 'pivotal' board changes

    This healthcare company is developing a blood test to detect colorectal cancer

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Share Gainers

    Rhythm Biosciences (ASX:RHY) share price rockets amid US$12bn market opportunity

    This healthcare company is targeting a lucrative market...

    Read more »

    RHY ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Rhythm Biosciences Ltd

    Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

    RHY Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Dec 2023 $0.16 $-0.02 -11.76% 84,250 $0.17 $0.17 $0.16
    07 Dec 2023 $0.17 $-0.02 -10.53% 150,847 $0.19 $0.19 $0.17
    06 Dec 2023 $0.19 $0.05 34.48% 114,732 $0.15 $0.20 $0.15
    05 Dec 2023 $0.15 $-0.02 -12.31% 373,013 $0.16 $0.16 $0.13
    04 Dec 2023 $0.16 $-0.01 -5.88% 33,051 $0.16 $0.17 $0.16
    01 Dec 2023 $0.17 $0.00 0.00% 9,628 $0.16 $0.17 $0.16
    30 Nov 2023 $0.17 $0.00 0.00% 53,584 $0.17 $0.17 $0.16
    29 Nov 2023 $0.17 $0.00 0.00% 247,752 $0.18 $0.18 $0.17
    28 Nov 2023 $0.18 $0.00 0.00% 54,154 $0.17 $0.18 $0.17
    27 Nov 2023 $0.17 $0.00 0.00% 508,483 $0.18 $0.19 $0.17
    24 Nov 2023 $0.18 $-0.01 -5.56% 26,423 $0.18 $0.18 $0.17
    23 Nov 2023 $0.18 $0.01 5.71% 251,780 $0.18 $0.18 $0.17
    22 Nov 2023 $0.18 $-0.02 -10.53% 276,211 $0.19 $0.19 $0.17
    21 Nov 2023 $0.19 $0.01 5.41% 57,861 $0.19 $0.20 $0.19
    20 Nov 2023 $0.19 $-0.02 -10.00% 328,886 $0.20 $0.20 $0.19
    17 Nov 2023 $0.20 $0.02 11.11% 46,106 $0.19 $0.20 $0.19
    16 Nov 2023 $0.18 $-0.02 -10.00% 667,370 $0.20 $0.21 $0.18
    15 Nov 2023 $0.20 $-0.01 -4.76% 313,871 $0.23 $0.23 $0.20
    14 Nov 2023 $0.21 $0.00 0.00% 154,138 $0.22 $0.23 $0.21
    13 Nov 2023 $0.21 $0.02 10.26% 360,861 $0.20 $0.23 $0.20
    10 Nov 2023 $0.20 $0.01 5.41% 470,739 $0.18 $0.21 $0.18
    09 Nov 2023 $0.19 $-0.01 -5.26% 97,939 $0.19 $0.19 $0.18

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    10 Oct 2023 Sue(Susan) MacLeman Issued 200,000 $61,000
    Issue of options.
    08 Aug 2023 Trevor Lockett Buy 1,125,000 $225,000
    Exercise of options.
    08 Aug 2023 Trevor Lockett Exercise 1,125,000 $225,000
    Exercise of options.
    30 Jun 2023 Otto Buttula Expiry 500,000 $205,000
    Options expired.
    30 Jun 2023 Louis (Lou) Panaccio Expiry 37,500 $15,375
    Options expired.
    30 Jun 2023 Trevor Lockett Expiry 125,000 $51,250
    Options expired.
    12 May 2023 Otto Buttula Buy 683,895 $248,245
    On-market trade.
    18 Jan 2023 Glenn Gilbert Issued 3,000,000 $2,925,000
    Employee Share Ownership Plan.
    18 Jan 2023 Rachel David Issued 150,000 $146,250
    Issue of options.
    04 Jan 2023 Otto Buttula Expiry 500,000 $530,000
    Options expired.
    04 Jan 2023 Louis (Lou) Panaccio Expiry 37,500 $39,750
    Options expired.
    04 Jan 2023 Trevor Lockett Expiry 125,000 $132,500
    Options expired.
    04 Jan 2023 Glenn Gilbert Expiry 500,000 $530,000
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Otto Leslie Steven Buttula Executive ChairmanExecutive Director Oct 2019
    Mr Buttula has had experience in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Ltd. He is a Director of HITIQ Limited (appointed 28 January 2021) and OncoSil Medical Limited (appointed 20 July 2021).
    Mr Louis (Lou) James Panaccio Non-Executive Director Aug 2017
    Mr Panaccio has management experience in business and healthcare services. Mr Panaccio is also on the board of Unison Housing Ltd. Mr Panaccio has more than twenty years experience as a board member of both public and private, for profit and not for profit companies. Previously, Mr Panaccio was the CEO of Melbourne Pathology and Monash IVF, and executive Chairman of Health Networks Australia.
    Ms Sue(Susan) MacLeman Non-Executive Director Jan 2023
    Mr MacLeman has more than 30 years experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development at Schering Plough Corporation (now Merck), Amgen, Bristol Myers Squibb and Mesoblast. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector. Sue is currently the Chair of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect). Sue is a Non Executive Director of Planet Innovation Holdings Ltd, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Sue is also appointed to several academic and government advisory boards. Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management.
    Dr Trevor John Lockett Technical director Nov 2018
    Dr Lockett has postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Dr Lockett has led research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Dr Lockett oversaw the research efforts which led to the technology that is to become ColoSTAT.
    Dr Rachel David Non-Executive Director Dec 2021
    Dr David is an experienced senior health and financial services sector executive. Dr David is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA). Dr David's career has spanned over 25 years during which she has delivered value by promoting policy change to address the economic problems and market failures in healthcare, relating to evidence based practice and access to new technologies. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.
    Ms Andrea Steele Company SecretaryGeneral Counsel Feb 2022
    Andrea Steele Company SecretaryGeneral Counsel

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Webinvest Pty Ltd 17,291,667 7.83%
    Ferndale Securities Pty Ltd 10,300,000 4.66%
    Loumea Investment Pty Ltd 8,052,520 3.65%
    Northern Star Nominees Pty Ltd 7,380,000 3.34%
    Newfound Investments Pty Ltd 6,819,729 3.09%
    HSBC Custody Nominees (Australia) Limited 6,515,269 2.95%
    Rojo Nero Capital Pty Ltd 4,323,751 1.96%
    Giokir Pty Ltd 3,661,470 1.66%
    Mr Hsien Michael Soo 3,305,403 1.50%
    Commonwealth Scientific & Industrial Research Organisation 2,500,000 1.13%
    Ms Natalie Louise Patterson 2,477,083 1.12%
    E & W Nominee Pty Ltd 2,207,941 1.00%
    Mr Daniel Eddington & Mrs Julie Eddington 2,123,532 0.96%
    Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss 2,000,000 0.91%
    Mrs Sarah Cameron 1,920,800 0.87%
    Jawaf Enterprises Pty Ltd 1,875,000 0.85%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 1,662,733 0.75%
    Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison 1,450,000 0.66%
    Mr Richard Stanley De Ravin 1,448,228 0.66%
    Mr Adrian Darby 1,357,124 0.61%